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INTRODUCTION 
Hepatocellular carcinoma (HCC) presents unique challenges and 
opportunities for patients and healthcare professionals globally. It 
is the 7th most common malignancy and 3rd leading cause of 
cancer death worldwide.1,2 In the United States, it ranks as the 5th 
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Background/Aims: The diagnosis and treatment plan for hepatocellular carcinoma (HCC) can be made from radiologic 
imaging. However, lesion detection may vary depending on the imaging modality. This study aims to evaluate the 
sensitivities of hepatic multidetector computed tomography (MDCT), magnetic resonance imaging (MRI), and digital 
subtraction angiography (DSA) in the detection of HCC and the consequent management impact on potential liver 
transplant patients.
Methods: One hundred and sixteen HCC lesions were analyzed in 41 patients who received an orthotopic liver 
transplant (OLT). All of the patients underwent pretransplantation hepatic DSA, MDCT, and/or MRI. The imaging results 
were independently reviewed retrospectively in a blinded fashion by two interventional and two abdominal radiologists. 
The liver explant pathology was used as the gold standard for assessing each imaging modality. 
Results: The sensitivity for overall HCC detection was higher for cross-sectional imaging using MRI (51.5%, 95% 
confidence interval [CI]=36.2-58.4%) and MDCT (49.8%, 95% CI=43.7-55.9%) than for DSA (41.7%, 95% CI=36.2-47.3%) 
(P=0.05). The difference in false-positive rate was not statistically significant between MRI (22%), MDCT (29%), and 
DSA (29%) (P=0.67). The sensitivity was significantly higher for detecting right lobe lesions than left lobe lesions for all 
modalities (MRI: 56.1% vs. 43.1%, MDCT: 55.0% vs. 42.0%, and DSA: 46.9% vs. 33.9%; all P<0.01). The sensitivities of the 
three imaging modalities were also higher for lesions ≥2 cm vs. <2 cm (MRI: 73.4% vs. 32.7%, MDCT: 66.9% vs. 33.8%, 
and DSA: 62.2% vs. 24.1%; all P<0.01). The interobserver correlation was rated as very good to excellent.
Conclusions: The sensitivity for detecting HCC is higher for MRI and MDCT than for DSA, and so cross-sectional imaging 
modalities should be used to evaluate OLT candidacy. (Clin Mol Hepatol 2016;22:450-457)
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and 9th most common cause of cancer death in men and women, re-
spectively.3 The incidence of HCC has continued to rise over the past 
several decades4,5 with approximately a 3% increase in incidence from 
2004 to 2008 according to the American Cancer Society.3 
Orthotopic liver transplant (OLT) eliminates the existing malig-
nancy and the diseased liver, a source for future malignancies. 
Transplant recipients have a dramatic increase in 5-year survival 
rate, increasing to 84%, compared to patients receiving localized 
treatment such as radiofrequency ablation (53% at early stage), 
partial hepatectomy (47%), and chemo- or radioembolization 
(35%).6 However, the costs involved in this curative treatment are 
not trivial. In 2008, the estimated total cost for OLT from 30 days 
pre-transplant to 180 days post-transplant was $523,400.7 The fi-
nancial burden, as well as limited availability of liver grafts, makes 
precise determination of transplant candidacy imperative and in 
many cases, imaging findings determine OLT candidacy. The radi-
ologist not only makes the diagnosis of HCC without histological 
confirmation,8,9 but also is responsible for determining the number 
and size of HCC tumors that govern a patient’s transplant candi-
dacy versus a palliative pathway.8,10-13 Milan and UCSF criteria 
have been established for the purpose of most appropriate alloca-
tion of liver transplant resources. Both of these criteria necessitate 
the patient should have three or fewer HCCs in order to qualify for 
OLT. In 2008, the Organ Procurement and Transplant Network 
(OPTN) and United Network for Organ Sharing (UNOS) revised the 
imaging criteria guidelines for diagnosis of HCC due to the con-
cern for a high number of false positives, which significantly im-
pacts transplant qualification and allocation of valuable resourc-
es.14 As a result, smaller lesions (1-2 cm) must be confirmed 
histologically or monitored for a longer period of time before 
transplantation preference points are allocated. 
Several studies have individually or comparatively evaluated the 
sensitivity for detecting HCCs by different imaging modalities; 
however, we have found no such study directly comparing sensi-
tivity of HCC detection by multidetector computed tomography 
(MDCT), magnetic resonance imaging (MRI), and angiography 
with liver explant pathology correlation. There are also discrepan-
cies in digital subtraction angiography (DSA) findings compared 
to pre-procedural cross sectional imaging, presenting a manage-
ment dilemma. One recent study describes the detection of “addi-
tional lesions” during angiography not previously identified on 
MDCT and subsequent empiric treatment of these “lesions” with 
chemoembolization.15 If this approach is used, will DSA findings 
affect transplant candidacy? The purpose of this study was to 
compare the sensitivity of cross sectional imaging and hepatic an-
giography to detect HCC based on the pathologic analysis of the 
explanted livers, and to investigate whether these imaging find-
ings will help determine the most appropriate management and 
treatment pathway for these patients.
MATERIALS AND METHODS
Patient selection criteria
This study was Health Insurance Portability and Accountability 
Act (HIPAA)-compliant, and approved by the Institutional Review 
Board prior to study commencement. A total of 125 consecutive 
patients with HCC who underwent OLT over a 4-year period were 
reviewed. Forty-one subjects who met the following inclusion cri-
teria were included: i) available MDCT and/or MRI images; ii) 
available hepatic angiography images; and iii) available liver ex-
plant pathology reports. The selection of transplant candidates was 
based on imaging diagnosis of HCC.11,16,17 Electronic medical records 
and picture archiving and communication system  images of each 
patient were reviewed to identify and include the liver transplant 
patients with both hepatic angiography and cross sectional imag-
ing (MDCT and/or MRI) performed prior to transplantation. Pre-
transplant hepatic angiograms were performed in all patients. Both 
MDCT and MRI were available for 31 patients, while the remaining 
10 patients had only one form of cross sectional imaging available 
for review, including 8 with MDCT and 2 with MRI.
MDCT
Dual- or triple-phase contrast-enhanced MDCT exams were 
performed on 16-64 slice computed tomography scanners (Phillips 
Brilliance CT Scanner; Cleveland, OH, USA) with 120 kVp and 
242-496 mA depending on adjustments for patient size. Images 
were acquired at standard intervals of 25-35 seconds (arterial 
phase), 70-80 seconds (portal venous phase), and, in two pa-
tients, 5 minutes (delayed phase) after the administration of 100-
120 mL nonionic iodinated contrast (Isovue-370; Bracco Diagnos-
tics Inc., Monroe Township, NJ, USA) via power injection (Medrad 
Stellant CT Injection Systems; Warrendale, PA, USA) at approxi-
mately 2.5-4 mL/second.
MRI
MRI was performed on 1.5 Tesla Magnetom Avanto magnetic 
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resonance scanners (Siemens Medical Solutions, Malvern, PA, 
USA). Standard sequences included axial T1-weighted in- and out-
of-phase images, fat-suppressed axial T2-weighted images 
(HASTE: Siemens Medical Solutions, Malvern, PA, USA), coronal 
T2-weighted images (HASTE), and fat-suppressed axial T1 Volu-
metric Interpolated Breath-hold Examination (VIBE; Siemens Med-
ical Solutions, Malvern, PA, USA) pre- and post-contrast images 
with a 320 x 168 matrix, 3 mm slice thickness, NEX=1, TR=4.61 
ms, TE=2.18 ms. Dynamic post-contrast images were obtained in 
arterial, portal venous, and 5 minute delayed phases using sample 
bolus triggering method. The timing of arterial phase for dynamic 
post-contrast images was determined based on aortic peak sam-
ple bolus timing (18-20 seconds). A 15 mL gadolinium contrast 
bolus (gadobenate dimeglumine, Multihance®, Bracco Diagnostics 
Inc., Monroe Township, NJ, USA) and 20 mL saline flush was ad-
ministered via power injection (Spectris Solaris EP MR Injection 
System, Medrad, Warrendale, PA, USA).
DSA
Hepatic angiography was performed for the purpose of local-
ized therapeutic planning and/or treatment with bland, chemo-, 
or radioembolization. Prior to each hepatic angiogram, the inter-
ventional radiologist reviewed cross sectional imaging and evalu-
ated the location of HCC tumor(s). Hepatic angiograms were per-
formed by one of four interventional radiologists with experience 
levels ranging from 11 to 30 years, using standard fluoroscopic 
DSA techniques and varying parameters. The majority of the 
studies were performed with dual plane flat panel digital angiog-
raphy (Infinix DP-I; Toshiba, Tustin, CA, USA). Images were ac-
quired during selective injection of nonionic iodinated contrast 
(Iopamidol®, Isovue 300, Bracco Diagnostics Inc., Monroe Town-
ship, NJ, USA) into celiac axis and/or common hepatic artery 
through coaxial microcatheters introduced via femoral artery 
sheath. In selected patients, super-selective DSA was also per-
formed in branching hepatic arteries for improved visualization of 
suspicious lesions or focal treatment. Injection of contrast was 
performed at varying rates and volumes by manual and/or power 
injection (Mark V ProVis Angiographic Injection System; Medrad, 
Warrendale, PA, USA). C-arm CT examination images were ex-
cluded from review. 
Pathology
Pathology reports of the explanted livers were used as the ref-
erence standard for confirmation of HCC(s). Liver explants were 
examined in whole and sectioned at 3-5 mm intervals in axial 
plane per standard surgical pathologic protocol. Nodules appear-
ing grossly suspicious or measuring greater than 10 mm are evalu-
ated by microscopic and histologic analysis with hemotoxylin and 
eosin staining. All pathology reports reviewed were approved by 
staff pathologists, most of which were examined by one of two 
experienced, dedicated hepatopathologists. Pathology reports 
were retrospectively reviewed, and the following data was ex-
tracted: total number of tumors, size and location of each tumor, 
and additional lesion characteristics (including presence of embo-
lization material). Notation of focal embolization material and un-
derlying malignant cellular change was considered as tumor. The 
reported pathologic results were compared to retrospective imag-
ing review results on a tumor-by-tumor basis according to loca-
tion, size and additional descriptors. 
Image review
MDCT, MRI and hepatic angiography images were grouped by 
modality and anonymized and randomized for review. Two fellow-
ship trained abdominal radiologists with 11 and 5 years of experi-
ence blindly reviewed the cross-sectional studies. American Asso-
ciation for the Study of Liver Diseases (AASLD) imaging criteria 
(arterial hypervascularity and venous and/or delayed phase wash-
out) were used for identification of HCC.17 If multiple cross sec-
tional exams of the same modality were performed prior to trans-
plantation, only exams performed closest to the date of transplant 
were included in the study. No comparison imaging or pathology 
reports were available during the review. 
Two interventional radiologists with 11 and 18 years of experi-
ence and special interest in interventional oncology reviewed the 
hepatic angiograms. Again, these studies were anonymized and 
randomized for independent review without comparison imaging. 
Only angiograms performed closest to the date of transplant were 
included in the study. Both sets of reviewers analyzed each imag-
ing study for the total number, size, and location of each suspect-
ed tumor (lobe and, when possible, Couinaud segment), and any 
additional pertinent descriptors (such as presence of suspected 
satellite lesions, nearby anatomic landmarks, etc). Specifically, the 
location of the lesions (identified as hypervascular masses) was 
determined by the arterial branching pattern from non-selective 
and selective angiogram image sets.
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Statistical analysis
Cohen’s kappa coefficient was used to determine inter-observer 
variability. A generalized linear mixed model was used to deter-
mine sensitivity of each test overall, as well as after separating tu-
mors by size (<2 cm versus ≥2 cm) and by location (right versus 
left lobe). Differences in sensitivity were considered significant if 
P<0.05. Statistical analysis for specificity of each modality was 
unable given the inability to produce a “true negative” value dur-
ing tumor detection. 
RESULTS
Patients and lesions
Among the 41 patients, 33 were men and 8 were women, with 
a mean age of 58 years (range: 29.4 to 72.1 years). According to 
pathologic analysis, a total of 116 HCCs were detected, with an 
average of 3 tumors per patient (range: 1 to 11 tumors). Location 
of tumor varied from the right lobe in 79, the left lobe in 34, the 
caudate lobe in 2, and an unspecified lobe (hilum) in one. The 
mean tumor size was 2.2 cm (range: 0.4-7.5 cm). The number of 
patients with small HCCs (<2 cm in size) was similar to that of pa-
tients with larger (≥2 cm) ones (n=61 and 55, respectively). The 
mean time interval between imaging and transplant, was 5.4 
months (range: 0.3-11.4 months) for MDCT, 6.3 months (range: 
0.2-17.1 months) for MRI, and 5.0 months (range: 0.1-20.5 
months) for hepatic angiography. Inter-observer agreement was 
excellent for DSA and very good for MDCT and MRI (Cohen’s kap-
pa coefficients of 0.83, 0.73, and 0.78, respectively).
Overall sensitivity
The sensitivity of tumor detection was calculated for each modality 
using a generalized linear mixed model, fit with the exam type as a 
fixed effect and the patients and lesions as random effects. The out-
come variable was lesion detection (identified as “yes” or “no”). The 
overall sensitivity of tumor detection for each modality, independent 
of tumor size or location, was 49.8% for MDCT, 51.5% for MRI, and 
41.7% for hepatic angiography as listed in Table 1. 
When comparing sensitivities of each modality in a pair-wise 
fashion, there was no statistically significant difference in sensitiv-
ity between MDCT and MRI (P=0.722). However, there was sta-
tistically significant difference between the sensitivity of MDCT 
and angiography (P=0.05), and between MRI and angiography 
(P=0.03) for HCC detection.
Sensitivity by size
The tumors were then divided into two categories based on size 
being greater or smaller than 2 cm. The sensitivity of each modal-
ity according to tumor size is listed in Table 2. Tumor detection 
was significantly greater by all modalities in identifying tumors ≥
2 cm (P<0.0001). The pair-wise comparison of sensitivities for 
small tumor detection demonstrated no significant difference be-
tween modalities (MDCT vs. MRI, P=0.857; MDCT vs. angiogra-
phy, P=0.065; MRI vs. angiography, P=0.123). Similarly, the pair-
wise comparison for detection sensitivity of tumors ≥2 cm also 
demonstrated no significant difference between modalities (MDCT 
vs. MRI, P=0.298; MDCT vs. angiography, P=0.423; MRI vs. an-
giography, P=0.069). 
Sensitivity by lobe
The tumors were also separated into two groups based on 
Table 2. Sensitivity of HCC detection by imaging modality according to tumor size.
Modality
HCC (<2 cm) HCC (≥2 cm)
Sensitivity 95% CI Sensitivity 95% CI
MDCT 33.8 25.8-41.8 66.9 58.7-75.2
MRI 32.7 23.9-41.6 73.4 64.4-82.4
Angiography 24.1 17.5-30.6 62.2 54.2-70.2
HCC, hepatocellular carcinoma; CI, confidence interval; MDCT, multi-detector computed tomography; MRI, magnetic resonance imaging.
Table 1. Overall sensitivity of HCC detection for each imaging modality
Modality Sensitivity 95% CI
MDCT 49.8 43.7-55.9
MRI 51.5 44.6-58.4
Angiography 41.7 36.2-47.3
HCC, hepatocellular carcinoma; CI, confidence interval; MDCT, multi-detector 
computed tomography; MRI, magnetic resonance imaging.
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which lobe they were located in. The sensitivity of each modality 
in relation to tumor location is listed in Table 3. The sensitivity of 
tumor detection was significantly greater by all modalities in iden-
tifying tumors in the right lobe compared to those in the left 
(P=0.0003). 
Sensitivity by lobe and size
When comparing the sensitivity of tumor detection by each mo-
dality according to location and size (<2 cm vs. ≥2 cm), there 
were significant differences. All modalities had greater sensitivity 
for identifying right lobe tumors (P=0.035) and tumors ≥2 cm 
(P<0.0001). Further, when accounting for both size and location 
(potential confounding variables), a statistically significant differ-
ence remained between imaging modalities (P=0.043). Pair-wise 
comparison accounting for size and location demonstrated a bor-
derline difference in the sensitivity between MDCT and angiogra-
phy (P=0.05) and a significant difference between MRI and angi-
ography (P=0.02). No statistical significance was found between 
sensitivity of MDCT and MRI (P=0.64) for detecting HCCs.
False positives
False positive tumors (those suspected to be HCC by imaging, 
but not present on pathology) were identified for each imaging 
modality. Twenty-nine percent of patients evaluated by angiogra-
phy had at least one false-positive lesion, whereas 29% of pa-
tients evaluated by MDCT and 22% of patients evaluated by MR 
had at least one false-positive lesion. False-positivite rates of 
three imaging modalities were not significantly different (P=0.67).
DISCUSSION
Liver transplantation has become a revolutionary, curative 
treatment for HCC. However, cost and resource limitation make 
it imperative to select the most appropriate graft recipients ac-
cording to evidence-based medicine and outcomes data. De-
spite the validated use of MDCT and MRI to evaluate and plan 
treatments for patients with HCC,8-11,13,18,19 discordant results 
may be discovered during angiography, resulting in unplanned 
treatment changes (Fig. 1). 
There is a wide range of sensitivities reported in the litera-
ture for detection of HCC on MDCT, MRI, and angiography. 
Studies comparing individual cross sectional imaging modali-
ties to explant pathology have demonstrated a range of sensi-
tivities: 50-75% for MDCT20-22 and 70-87% for MR.21-23 Angi-
ography, albeit less well documented, is shown to have a 
diagnostic accuracy ranging from 33 to 77%24-27 with drastical-
ly lower sensitivity (18%) for lesions ≤2 cm.25 Those studies 
whose sensitivities were greatest had the common methodolo-
gy of communication of pre-transplant imaging findings be-
tween the radiologist and pathologist at the time of pathologic 
sectioning and evaluation,21,23,24 possibly leading to reference 
standard bias towards the imaging findings. Our study results 
correspond to the lower end of these spectrums for each imag-
ing modality (49.8% for MDCT, 51.5% for MR, and 41.7% for 
angiography). This may be due to lack of histologic bias and 
inclusion of lesions smaller than 2 cm. As widely discussed 
throughout the literature, there is a much greater sensitivity for 
detection of larger HCC tumors,15,20-25 specifically those >2 cm. 
This is intuitive given the possible obscuration or less typical 
imaging characteristics of smaller lesions, including volume av-
eraging, decreased hepatic arterial vascularization or con-
founding appearance of the underlying hepatic parenchyma. 
The results of our study also demonstrated this correlation be-
tween improved sensitivity for tumors ≥2 cm (66.9% vs. 
33.8% for MDCT and 73.4% vs. 32.7% for MRI, and 62.2% 
vs. 24.1% for angiography). Interestingly, there was a statisti-
cally greater sensitivity in detection of tumors in the right he-
patic lobe versus the left hepatic lobe regardless of size or im-
aging modality (55.0% vs. 42.0% for MDCT, 56.1% vs. 43.1% 
for MRI, and 46.9% vs. 33.9% for angiography). These find-
ings have not previously been reported in the literature and 
Table 3. Sensitivity of HCC detection by imaging modality according to tumor location.
Modality
Right lobe Left lobe 
Sensitivity 95% CI Sensitivity 95% CI
MDCT 55.0 48.3-61.6 42.0 34.2-49.8
MRI 56.1 48.8-63.4 43.1 34.5-51.7
Angiography 46.9 40.7-53.1 33.9 26.6-41.3
HCC, hepatocellular carcinoma; CI, confidence interval; MDCT, multi-detector computed tomography; MRI, magnetic resonance imaging.
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Figure 1. Imaging assessments in a 47-year-old female with cirrhosis and three histologically proven HCCs: (A) DSA, (B) arterial-phase MDCT, (C) portal-
venous-phase MDCT, and (D, E) 5-minute delayed-phase MRI of the liver. (A) DSA image of the right hepatic lobe after subselective right hepatic artery 
injection, demonstrating two round contrast blushes (white arrows). The medial arrow corresponds to an accurately identified HCC, and the lateral arrow 
corresponds to a region of posttreatment change in the prior external beam radiation. Numerous additional small round hypervascular blushes (black 
arrows) were misidentified as multifocal HCCs. (B) Arterial-phase MDCT axial image of the liver, demonstrating round hypervascular lesions in the pos-
teromedial right hepatic lobe and an anterior left medial hepatic lobe (black arrows) that were correctly identified as HCCs. The additional geographic 
enhancement in the lateral right hepatic lobe (white arrow) was hyperemia due to prior external beam radiation therapy for a previously identified HCC. 
No additional lesions were identified corresponding to suspicious multifocal lesions identified by DSA. (C) Portal-venous-phase MDCT axial image of the 
right hepatic lobe at the same level as Fig. 1B, demonstrating isoenhancement in the areas of histologically proven HCCs (black arrows). There was no 
washout during the portal venous phase, and diagnoses of HCCs were based on arterial hyperenhancement in a cirrhotic liver. (D) Five-minute delayed-
phase postcontrast T1-weighted MRI image demonstrating characteristic washout in the posteromedial right hepatic lobe (black arrow). This accurately 
identified tumor corresponds to the right hepatic lobe lesion identified on DSA and MDCT. (E) Five-minute delayed-phase postcontrast T1-weighted 
MRI image demonstrating characteristic washout in the anterior left medial hepatic lobe (black arrow), accurately identified as HCC. There is again mild 
persistent enhancement of the lateral right hepatic lobe at the site of prior external beam radiation. Again, no additional HCCs were identified corre-
sponding to the suspicious multifocal disease seen on DSA. The white arrow in 1E denotes the region of postradiation change, which does not demon-
strate washout. HCC, hepatocellular carcinoma; DSA, digital subtraction angiography; MDCT, multidetector computed tomography.
A
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could possibly be explained by streamlining of blood flow to 
the right hepatic lobe.28,29
Unique to the aforementioned literature, our study directly 
compares the sensitivities of MDCT, MRI and angiography 
within the same patient population. While comparing the re-
sults of each modality in a pair-wise fashion, we found a sta-
tistically significant difference between MRI and angiography 
(P=0.03), which is an addition to the previous studies report-
ing superiority of MRI over CT.21,30,31 Similarly, once adjusted 
for differences in lesion size and location, pair-wise comparison 
demonstrated the greatest and most statistically significant 
dif ference between MRI and angiography sensitivities 
(P=0.02), as well as a borderline significance in the difference 
between MDCT and angiography (P=0.05). These findings 
suggest that angiography alone should not be considered an 
equivalent imaging method used to affect or change the treat-
ment pathway of these patients.
We also assessed the number of false positive lesions as an-
other measure of comparing modality-based accuracy. False 
positive lesions have been evaluated in prior modality-specific 
studies of HCC detection.15,23,32 These studies demonstrate up 
to 8% false positive lesions for MDCT,23 31% for MR,32 and 
48% for C-arm CT angiography.15 However, none of these 
studies compares the false positive lesions detected by each of 
these modalities in the same patients. Our study compared the 
false positive lesions detected in each patient to explant pa-
thology and revealed no statistically significant difference be-
tween these modalities (angiography; 29% of patients [n=12], 
MDCT; 29% of patients [n=12] and MRI; 22% of patients 
[n=9]). 
The limitations of our study include the retrospective design 
and variable time elapsed between each imaging modality and 
from imaging to transplant. The exclusion criteria for our study 
did not address time elapsed between imaging exams or be-
tween imaging and transplant, and a more selective group of 
patients would likely improve the accuracy of each modality. 
There were variable angiographic image acquisition tech-
niques, largely due to exam indication (diagnostic exams for 
treatment planning versus exams for catheter-directed thera-
pies) and patient cooperation. This may have led to falsely low 
sensitivity at time of review that would not be an accurate de-
piction of clinical angiography exams. 
In summary, our results have demonstrated the MR and 
MDCT to be more accurate imaging for transplant evaluation 
and treatment planning. Therefore, additional angiographic 
findings at the time of interventional treatment should be veri-
fied with cross sectional studies before changing the patient’s 
management. Prospective evaluation of cross sectional and in-
terventional angiographic imaging should be pursued to opti-
mize the evaluation of each exam’s sensitivity and establish the 
most appropriate treatment planning pathway for liver trans-
plant candidates with HCC.
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